恆指跌幅擴至擴至逾700點 醫藥板塊榮辱互見 平安好醫生(01833.HK)續漲6%破頂
武漢的新型冠狀病毒肺炎個案持續上升，國家衛健委高級專家組組長鍾南山認為，武漢的新型冠狀病毒肺炎肯定有人傳人，建議暫不要去武漢。瑞銀指，無藥企可直接受惠武漢肺炎事件，但料可間接提振疫苗及身體檢查等行業。內地醫藥生物、免疫治療、流感、病毒防治及中藥板塊今天逆市續升1.6%-2.6%。
本港醫藥及醫療板塊榮辱互見。平安好醫生(01833.HK)突破去年10月所創上市高位64.65元，最高見68.2元，現造66.85元，續升5.9%。
旗下兩種藥品於第二批集中採購中標的新華製藥(00719.HK)連漲第三天高見4.3元創逾八個月高，現造4.22元，續升2.4%；其A股續升8.7%曾高見9.37元人民幣創逾九個月高。
研發中藥注射疫苗的神威藥業(02877.HK)也反覆連升第三天，最高見8.02元，現造7.95元，續升3%；四環醫藥(00460.HK)高見1.01元，現造0.99元，續升2.1%。
石四藥(02005.HK)反覆連升第五天，最高見7.23元，創逾四個月高，現造7.17元，升2.3%。獲瑞信升價至14.05元兼重申「跑贏評級」的康哲藥業(00867.HK)高見12.48元，創兩個月高，現造12.222元，回升1.7%。
相反，昨天公布旗下有三種藥品中標集中採購的東陽光藥(01558.HK)承昨天飆升19%強勢，今早進一步升破2018年2月所創上市高位51.6元，最高見54.45元遇阻，掉頭曾倒跌6.7%，現造47.55元，回吐4.2%。
藍籌中生製藥(01177.HK)今早高開見12.46元，未能突破昨天所創逾年半高位12.5元，掉頭回吐2.1%，報12.06元。綠葉製藥(02186.HK)失守牛熊線(6.07元)，現造6.02元，反覆續吐2.3%。
穆迪降香港主權評級至「Aa3」以反映港府管治能力轉差，恆指午後跌幅進一步擴至逾700點或近2.5%，報28,078；國指跌幅擴至近2.6%報11,036。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
